December 1, 2006 -- Pfizer established a five-year, $100 million partnership with the Scripps Research Institute of San Diego for basic science; Affymax set the terms for its upcoming IPO; Crucell landed $230 million worth of contracts to produce vaccines over the next three years; Cytokinetics said the oral form of its prospective heart failure drug passed a bioavailability study, and Monogram and Pfizer will expand their program to make maraviroc available to AIDS patients who become resistant to other treatments. The Centient Biotech 200™ fell 11 points to 3946, a drop of .28%. More details...
